IPO - GRI BIO, Inc.

Form Type: 424B4

Filing Date: 2025-04-02

Corporate Action: Ipo

Type: New

Accession Number: 000162828025016067

Filing Summary: GRI Bio, Inc. is conducting an initial public offering (IPO) of 202,000 shares of common stock along with various warrants including Series E-1, E-2, and E-3 warrants. The offering price per share is set at $3.60, with a combined offering price including the accompanying warrants. In addition, 1,186,888 pre-funded warrants will be available for purchase at a reduced exercise price of $0.0001 per share for investors exceeding 4.99% of ownership in the company. This prospectus outlines the terms of the offering scheduled to close on April 2, 2025, and details the conditions surrounding the issuance of these securities, including the roles of the placement agent, market expectations, and previous regulatory approvals. Notably, the document highlights the February 2025 reverse stock split, which adjusted the outstanding shares significantly going into this IPO. The summary also identifies the company's focus on innovative therapies targeting severe diseases associated with immune dysregulation, emphasizing the unexpected progression in the clinical development strategy and the risks associated with the IPO. Investors are cautioned regarding potential dilution and the speculative nature of the investment in warrants.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-04-02

Corporate Action: Ipo

Type: New

Accession Number: 000162828025016066

Filing Summary: On April 1, 2025, GRI Bio, Inc. commenced a best efforts public offering of an aggregate of 202,000 shares of common stock, 1,186,888 pre-funded warrants, and various series warrants for a total anticipated net proceeds of approximately $4.2 million. The company intends to use these funds for working capital, product development, and general corporate purposes. The offering is planned to close around April 2, 2025. The securities include detailed terms regarding exercise prices and expiration dates for the warrants, along with conditions outlined in a securities purchase agreement. The firm anticipates satisfying customary closing conditions, and there are associated risks involved in the offering and future projections concerning clinical development and financial sufficiency.

Document Link: View Document